Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bioAffinity Technologies Inc BIAF

Healthcare Medical Instruments & Supplies
bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its... see more

Recent & Breaking News (NDAQ:BIAF)

bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023

Business Wire March 24, 2023

bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications

Business Wire February 13, 2023

bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research

Business Wire January 24, 2023

bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments

Business Wire January 4, 2023

Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)

PR Newswire December 19, 2022

bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench

Business Wire December 15, 2022

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

Business Wire December 1, 2022

bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update

Business Wire November 14, 2022

bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company's Scientific and Medical Advisory Board

Business Wire November 10, 2022

bioAffinity Technologies to Report Third Quarter 2022 Financial Results

Business Wire November 8, 2022

bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia

Business Wire October 25, 2022

bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference

Business Wire October 12, 2022

bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M

Business Wire September 28, 2022

bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE

Business Wire September 14, 2022

WallachBeth Capital Announces Closing Of bioAffinity Technologies, Inc. $7.8 Million Initial Public Offering

PR Newswire September 6, 2022

bioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public Offering

Business Wire September 6, 2022

WallachBeth Capital Announce Pricing Of bioAffinity Technologies IPO At $6.125 Per Unit

PR Newswire September 1, 2022

bioAffinity Technologies Announces Pricing of IPO

Business Wire September 1, 2022